FDA Approves Rybrevant Faspro for Head and Neck CancerNovember 6, 2026 Health 3 Views The FDA has approved Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell carcinoma who have progressed on prior therapies.
